Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407407 · ClinicalTrials.gov registry record · Phase 1
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00407407 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 6 participants.
The verdict
NCT00407407, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly and every 3-weeks ABI-007 in combination with carboplatin (area under the curve \[AUC\]=6) in patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Interventions
- DRUG Carboplatin
- DRUG ABI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-11-01 |
| Est. Completion | 2008-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00407407
The ClinicalTrials.gov registry entry for NCT00407407 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT00407407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00407407 about?
NCT00407407 is a clinical study titled "ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma". The primary purpose of this study is to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly and every 3-weeks ABI-007 in combination with carboplatin (area under the curve \[AUC\]=6) in patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
What is the current status of trial NCT00407407?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2006-11-01. Estimated completion is 2008-02-01.
What interventions are being tested in trial NCT00407407?
The interventions under investigation include: Carboplatin (DRUG), ABI-007 (DRUG).
Who is sponsoring clinical trial NCT00407407?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.